Months after IPO, Novartis spinout resTORbio wins on PhIIb data — stock soars

Just six months after its debut on the Nasdaq, resTORbio is trotting out late-stage data this morning for its lead drug candidate — a TORC1 inhibitor they’re hoping will prevent respiratory infections in elderly folks. While it flopped in a combo trial, the company’s drug met its primary endpoint when tested by itself.